* eFFECTOR Therapeutics Inc EFTR.OQ EFTR.O is expected
to show
a fall in quarterly revenue when it reports results on August 7
(estimated).
*
* Refinitiv's mean analyst estimate for eFFECTOR
Therapeutics Inc
is for a loss of 20 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for eFFECTOR
Therapeutics Inc is $7, above its last closing price of $0.73.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.18 -0.14 -0.24 Missed -76.5
Dec. 31 2023 -0.23 -0.24 -0.22 Beat 7.6
Sep. 30 2022 -0.21 -0.21 -0.23 Missed -7.6
Jun. 30 2022 -0.16 -0.16 -0.17 Missed -5.5
Mar. -0.24 -0.24 0.07 Beat 129.5
31 2022
Dec. 31 2021 -0.24 0.44 Beat 283.2
Sep. 30 2021 -0.25 -0.20 0.42 Beat 313.6
This summary was machine generated August 4 at 13:29 GMT. All
figures in US dollars unless otherwise stated